Neurotech Appoints Beth Marsh as Chief Commercial Officer

April 21, 2025

Cumberland, R.I., April 21, 2025 – Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced the appointment of Beth Marsh as Chief Commercial Officer, effective April 28, 2025. In this role, Beth will lead the commercial organization, including preparing for the U.S. launch of ENCELTO™ (revakinagene taroretcel-lwey), the first and only approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel).

Beth is an established commercial and strategic business executive with more than two decades of leadership experience and expertise in ophthalmology and retina.

“We are delighted to welcome Beth to Neurotech during this important time as we prepare for the availability of ENCELTO to patients this June,” said Richard Small, Chief Executive Offer. “I am confident that Beth’s expertise in launching new therapies that address unmet needs, and her extensive network and leadership in the retina community will help us quickly scale up our commercial efforts for a successful launch.”

“This is an important and transformative time to join Neurotech as the company prepares for commercialization of the first and only approved treatment for adults suffering with MacTel,” said Beth. “Neurotech has a strong commercial organization and infrastructure in place, and I look forward to partnering with a talented team to achieve the successful launch of ENCELTO. It is an honor to join an organization focused on developing transformative therapies for chronic eye diseases.”

Beth joins Neurotech from Apellis Pharmaceuticals, where she served as Vice President, North America Sales and Marketing in Ophthalmology, leading the commercial U.S. launch for SYFOVRE, the first approved treatment for geographic atrophy secondary to age-related macular degeneration. Previously, she served in commercial leadership roles at Shire / Takeda Pharmaceuticals as Global Product Strategy Lead, Ophthalmology accountable for the comprehensive commercial strategy and launch readiness for two development-stage ophthalmic programs. Beth’s earlier experience included commercial and business development leadership roles at Aciex Therapeutics, Johnson & Johnson Vision Care, and Santen. She also volunteers as a non-profit leader and past president of OWL: Advancing diversity in leadership in ophthalmology. Beth earned a B.S. in Business Administration in Marketing from Miami University.

About Macular Telangiectasia Type 2 (MacTel)
Macular Telangiectasia Type 2 (MacTel), or idiopathic macular telangiectasia type 2, is a bilateral, neurodegenerative disease in adults with characteristic localized retinal degeneration that cause the gradual loss of cells in the retina, resulting in vision loss and secondary alterations of the retinal vasculature, the network of blood vessels that supplies oxygen and nutrients to the retina.

About Encapsulated Cell Therapy (ECT)
Neurotech's ECT platform is a cell-based gene therapy delivery system designed to provide long-term, sustained delivery of therapeutic proteins for the treatment of chronic eye diseases. This versatile platform consists of a small, semi-permeable capsule containing proprietary allogeneic retinal pigment epithelium (RPE) cells genetically engineered to produce specific therapeutic proteins for targeted disease treatment. The capsule is surgically implanted. Once in place, the capsule's semi-permeable exterior membrane allows essential nutrients to enter, while also permitting the therapeutic proteins to exit into the eye where they can travel to the retina located at the back of the eye. The exterior membrane protects the encapsulated RPE cells from the host's immune system, contributing to their survival and functionality over time.

About Neurotech Pharmaceuticals, Inc
Neurotech Pharmaceuticals, Inc. is a private biotech company focused on developing transformative therapies for chronic eye diseases. The core platform technology, Encapsulated Cell Therapy (ECT), is a first-in-class, drug delivery platform designed to slow the progression of Macular Telangiectasia Type 2 (MacTel) and other chronic eye diseases. ENCELTO™ (revakinagene taroretcel-lwey) is approved in the United States for the treatment of adults with idiopathic Macular Telangiectasia Type 2 (MacTel).

About ENCELTO™
ENCELTO is an encapsulated cell-based gene therapy. It is a small capsule, about the size of a grain of rice, that is placed inside the eye to release a protein called recombinant human ciliary neurotrophic factor (rhCNTF) that can directly reach the retina, the light sensitive part of the eye. The capsule contains living cells that have been genetically modified to continuously produce and release rhCNTF. This protein helps protect certain cells in the retina, supporting their health and reducing the loss of light-sensing cells known as photoreceptors.

ENCELTO is used to treat adults with idiopathic Macular Telangiectasia Type 2 (MacTel); a retinal disease that causes progressive vision loss. Your eye surgeon will assess your vision and review your medical history to determine if ENCELTO is the right treatment for you.

IMPORTANT SAFETY INFORMATION

Who should not receive an ENCELTO surgical implant?
ENCELTO has not been tested in pediatric patients or pregnant women.

The outpatient surgical procedure should not be performed if you are currently experiencing an active or suspected eye infection.

You should not receive ENCELTO if you have a known hypersensitivity to Endothelial Serum Free Media (Endo-SFM).

Before receiving ENCELTO, tell your eye surgeon about all your medical conditions, including:

- Are pregnant or plan to become pregnant. Although studies have shown that rhCNTF does not enter the bloodstream, its effects on an unborn baby have not been fully studied.
- Are breastfeeding or plan to breastfeed. It is not known if rhCNTF passes into your breast milk.
- Any current infections.
- Are currently taking or have recently taken medicines that lower the chance of blood clots forming in the body such as warfarin, low or regular doses of aspirin, or nonsteroidal anti-inflammatory drugs (NSAID).

How is ENCELTO administered?
ENCELTO is inserted into the eye as an outpatient surgical procedure performed by an eye surgeon experienced in vitreoretinal surgery. If removal of ENCELTO is necessary, the removal surgery must also be done by an eye surgeon experienced in vitreoretinal surgery in an operating room as an outpatient surgery.

What should I avoid while taking ENCELTO?
Immediately post-operative:

- Avoid heavy lifting (over 20 pounds) for one week.
- Keep water out of the eye (e.g., close your eye while showering) for one week.
- Protect your eyes by wearing glasses or protective eyewear during the day and using an eye shield at night for one week.
- Do not drive or use machinery until the eye shield has been removed and your eye surgeon informs you that your vision has recovered to an acceptable level.

Post-operative care:

- Use a topical antibiotic solution at a frequency of 1 drop four times a day for 7 days.
- Use a steroid drop taper of prednisolone acetate 1% (or equivalent) starting the day after surgery with the following taper:
    - 1 drop four times a day for the first 7 days;
    - 1 drop three times a day for the next 7 days;
    - 1 drop two times a day for the next 7 days;
    - 1 drop once a day for the last 7 days.

Magnetic Resonance (MR) Conditional Information

IMPORTANT: ENCELTO is MR Conditional
You will receive an implant card, which should be shown to your imaging technician if you need Magnetic Resonance Imaging (MRI) at any time while the ENCELTO implant is in your eye. The card will include details about the ENCELTO implant, the date of insertion, and on the back, instructions for the imaging technician to access important MRI safety information.

What are the possible side effects of ENCELTO?
Please follow all post-operative instructions given by your eye surgeon and ensure you attend all follow-up visits as recommended.

Potential side effects:

Please be advised that ENCELTO and the surgical insertion has related risks such as, but not limited to, endophthalmitis (eye infection), retinal tear and detachment (retina tears and potentially separates from the eye wall resulting in vision loss), vitreous hemorrhage (bleeding within the central cavity of the eye), implant extrusion (the ENCELTO begins to work its way out of the way), suture related issues (such as suture related eye irritation or exposure of sutures), temporary or permanent loss of vision, accelerated cataract formation (clouding of the lens of the eye), and delayed dark adaptation (the ability of the eye to adjust from bright lighting conditions to dark lighting conditions).

If delayed dark adaptation occurs, it is unknown for how long these symptoms will be experienced. Take the following safety precautions:

- Driving: Delayed dark adaptation may impair one's ability to see objects, pedestrians, or road sign signs when moving rapidly from a brightly lit environment to a dimly lit environment (for example, entering a tunnel during the daytime).
- Navigating in the Dark: Take caution when moving from bright to dark areas, such as entering a dark room or stepping outside at dusk. Consider using flashlights, nightlights, or motion-activated lighting at home.
- Consider wearing sunglasses or tinted lenses in bright environments to reduce the impact of transitioning from light to dark.

It is common to experience the following symptoms following ENCELTO surgery:

- Sensation of something in the eye (i.e., foreign body sensation)
- Eye redness
- Eye irritation
- Eye dryness
- Eye discharge
- Mild to moderate eye pain or discomfort
- Floaters (small spots or shapes that appear in your vision)
- Headache

When to Seek Eye Surgeon Advice

You are to seek immediate care from an eye surgeon if there are sudden changes in your vision, such as an increase in floaters, the appearance of "spider webs," flashing lights, sensitivity to light, loss of vision or visual field, progressively worsening eye pain, or increasing discharge/drainage from the eye as these symptoms could be a sign of a more serious issue.

Call your eye surgeon for medical advice about side effects. You may report side effects to the Food and Drug Administration (FDA) at 1-800-FDA-1088.

Please see full Prescribing Information and Patient Information for ENCELTO.

Corporate Contact:
Laurie Ferguson, Chief Communications Officer
Phone: 401-556-8649
Email: l.ferguson@neurotechusa.com